ClinicalTrials.gg
CompletedNCT04716634Updated Mar 25, 2025Results posted

Efficacy and Safety of Tislelizumab in Combination With Fruquintinib in Participants With Selected Solid Tumors

A Phase 2 interventional study of Tislelizumab and Fruquintinib in Advanced Solid Tumors, sponsored by BeiGene. Completed at 13 sites in 2 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-03-25.

Sponsored by BeiGene · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
84
Allocation
Non-randomized
Ages
18 Years and older
Sex
All
01

Study summary

This was an open label, multicenter, Phase 2 study designed to assess the efficacy and safety of tislelizumab in combination with fruquintinib in participants with advanced or metastatic, unresectable gastric cancer (GC), or colorectal cancer (CRC) or non-small cell lung cancer (NSCLC). The study was conducted in 2 parts. Part 1 was the safety run-in stage to determine dose-limiting toxicity (DLT) and recommended Phase 2 dose (RP2D). Part 2 assessed the preliminary efficacy of tislelizumab in combination with fruquintinib in participants as measured by the overall response rate (ORR) and other efficacy and safety profiles.

Read the detailed description

This was an open label, multicenter, Phase 2 study designed to assess the efficacy and safety of tislelizumab in combination with fruquintinib in patients with advanced or metastatic, unresectable GC, and CRC or NSCLC. The study was conducted in 2 parts.

Part 1 of the study was the safety run-in stage which assessed dose-limiting toxicities (DLTs) and RP2D. Part 2 began at RP2D. Participants enrolled in Part 1 at RP2D were counted towards Part 2; up to approximately 30 patients per cohort were enrolled at RP2D.

The primary outcome measure of the study was ORR as assessed by the investigator as per response evaluation criteria in solid tumors (RECIST) version (v) 1.1. Tislelizumab and fruquintinib were administered until disease progression, intolerable toxicity, death, withdrawal of consent or until the study terminates.

02

Conditions studied

  • Advanced Solid Tumors

Keywords

  • Solid tumors
03

In context

Lead sponsor

BeiGene is the lead sponsor of 125 studies on the registry; 2 are open to participants now.

Of its 55 completed or terminated interventional studies of FDA-regulated products, 32 (58%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Key Inclusion Criteria:

  1. Signed form (ICF) and able to comply with study requirements.
  2. At least 1 as defined by v1.1
  3. Tumor tissue (archival tumor tissues as formalin-fixed paraffin-embedded blocks or approximately 15 unstained slides) for central laboratory assessment
  4. (ECOG) Performance Status less than or equal to (\<=) 1
  5. or cytologically confirmed, advanced or , unresectable adenocarcinoma of gastric or esophagogastric junction or colon or rectum, and histologically or cytologically confirmed, locally advanced (Stage IIIB) not amenable to curative surgery or radiotherapy, or metastatic (Stage IV) NSCLC

Key Exclusion Criteria:

  1. Had at screening any central nervous system metastasis and/or
  2. Prior therapy targeting , PD-1, PD-L1 or programmed cell death protein ligand-2 (PD-L2) or any other antibody or drug specifically targeting T-cell costimulation or checkpoint pathways
  3. Prior treatment with VEGFR-TKI or anti-VEGFR antibody (eg, ramucirumab)
  4. Received more than 1 for advanced or metastatic, unresectable adenocarcinoma of gastric or esophagogastric junction, or more than 2 lines of systemic treatment for advanced or metastatic, unresectable adenocarcinoma of the colon or rectum, or prior systemic therapy for advanced or metastatic NSCLC
  5. Active diseases or history of autoimmune diseases that may relapse, or history of interstitial lung disease, noninfectious pneumonitis, or uncontrolled lung diseases including but not limited to pulmonary fibrosis, acute lung diseases, etc.

NOTE: Other protocol defined Inclusion/Exclusion criteria may apply.

Terms in these criteria, in plain language(10)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Leptomeningeal disease

Cancer that has spread to the leptomeninges, the thin layers covering the brain and spinal cord, and the fluid between them. It is not the same as brain metastases.

Criteria often treat it separately, and many studies leave it out even where treated brain metastases are allowed.

PD-1, PD-L1 and checkpoint inhibitors

PD-1, PD-L1 and CTLA-4 are proteins that act as brakes on the immune system. Checkpoint inhibitors, such as pembrolizumab or nivolumab, block them so the immune system can attack a cancer.

PD-L1 can also be measured in a tumor sample. Some scores count stained tumor cells only (TPS); others also count certain immune cells (CPS). The study names the score and the minimum it uses.

Line of therapy

A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.

“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
84 participants (actual)

Study arms

  • Experimental
    Gastric Cancer (GC): Tislelizumab and Fruquintinib

    Participants with advanced or metastatic, unresectable GC received fruquintinib 5 milligrams (mg) daily (3 weeks receiving fruquintinib followed by 1 week off) in combination with tislelizumab 300 mg intravenously on Day 1 of every 4-week cycle (each cycle of 28-days) until disease progression, unacceptable toxicity, or withdrawal for other reasons, whichever occurred first.

    Drug: Tislelizumab · Drug: Fruquintinib

  • Experimental
    Colorectal Cancer (CRC): Tislelizumab and Fruquintinib

    Participants with advanced or metastatic, unresectable CRC received fruquintinib 5 mg daily (3 weeks receiving fruquintinib followed by 1 week off) in combination with tislelizumab 300 mg intravenously on Day 1 of every 4-week cycle (each cycle of 28-days) until disease progression, unacceptable toxicity, or withdrawal for other reasons, whichever occurred first.

    Drug: Tislelizumab · Drug: Fruquintinib

  • Experimental
    PD-L1 + NSCLC: Tislelizumab and Fruquintinib

    Participants with programmed cell death protein ligand-1 (PD-L1) expression, and advanced or metastatic, unresectable non-small cell lung cancer (NSCLC) received fruquintinib 5 mg daily (3 weeks receiving fruquintinib followed by 1 week off) in combination with tislelizumab 300 mg intravenously on Day 1 of every 4-week cycle (each cycle of 28-days) until disease progression, unacceptable toxicity, or withdrawal for other reasons, whichever occurred first.

    Drug: Tislelizumab · Drug: Fruquintinib

Interventions

  • Tislelizumab is a humanized, immunoglobulin G4 (IgG4)-variant monoclonal antibody against PD 1.

    Also known as: BGB-A317

  • Fruquintinib is a potent, oral VEGFR tyrosine kinase inhibitor (TKI)

    Also known as: HMPL-013

06

What researchers measure

Primary outcomes

  1. Part 1: Number of Participants With Dose Limiting Toxicities (DLTs)

    A DLT was defined as 1 of the following toxicities (Grade 3 or 4 Hematologic or Nonhematologic toxicities) occurring during the DLT assessment window and considered by the investigator to be related to 1 or more study drugs. All toxicities or adverse events (AEs) were graded according to the National Cancer Institute-Common Terminology Criteria for Adverse Events version 5.0 (NCI-CTCAE v5.0).

    Time frame: Up to 28 Days

  2. Part 1: Recommended Phase 2 Dose (RP2D)

    RP2D for Part 2 was determined by evaluating safety and DLTs in Part 1 participants.

    Time frame: Up to 28 Days

  3. Objective Response Rate (ORR) as Assessed by the Investigator Based on Response Evaluation Criteria in Solid Tumors (RECIST) Version (v)1.1

    ORR was defined as the percentage of participants achieving a best overall response (BOR) of complete response (CR) or partial response (PR). Per RECIST v1.1., CR was defined as disappearance of all target lesions. Any pathological lymph nodes (whether target or non-target) must have reduction in short axis to less than (\<) 10 millimeters (mm). PR was defined as at least a 30 percent (%) decrease in the sum of diameters of target lesions, taking as reference the baseline sum diameters.

    Time frame: From date of randomization until the date of first documented progression or death from any cause, whichever came first (up to 2 years and 9 months)

Secondary outcomes

  1. Progression-Free Survival (PFS) as Assessed by Investigator Based on RECIST v1.1

    PFS was defined as the time from the date of the first dose of study drug(s) to the date of the confirmed documentation of progressive disease (PD) or death, whichever occurs first. Median PFS was estimated using the Kaplan-Meier method. Per RECIST v1.1, PD was defined as at least a 20% increase in the sum of diameters of target lesions, taking as reference the smallest sum on study.

    Time frame: From date of first dose of study drug until the date of first documented progression or death from any cause, whichever came first (up to 2 years and 9 months)

  2. Disease Control Rate (DCR) as Assessed by the Investigator Based on RECIST v1.1

    DCR was defined as the percentage of participants whose best overall response is CR, PR, or stable disease (SD) as assessed by investigator as per RECIST v1.1. Per RECIST v1.1., CR was defined as disappearance of all target lesions. Any pathological lymph nodes (whether target or non-target) must have reduction in short axis to \< 10 mm. PR was defined as at least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum diameters. SD: Neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD, taking as reference the smallest sum diameters while on study.

    Time frame: From date of randomization until the date of first documented progression or death from any cause, whichever came first (up to 2 years and 9 months)

  3. Clinical Benefit Rate (CBR) as Assessed by the Investigator Based on RECIST v1.1

    CBR was defined as the percentage of participants whose best overall response is CR, PR, or durable stable disease (SD) as assessed by the investigator per RECIST v1.1. Per RECIST v1.1., CR was defined as disappearance of all target lesions. Any pathological lymph nodes (whether target or non-target) must have reduction in short axis to \< 10 mm. PR was defined as at least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum diameters. SD: Neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD, taking as reference the smallest sum diameters while on study.

    Time frame: From date of randomization until the date of first documented progression or death from any cause, whichever came first (up to 2 years and 9 months)

  4. Duration of Response (DOR) as Assessed by The Investigator Based on RECIST v1.1

    DOR was defined as the time from the first occurrence of documented objective response to the time of progression as assessed by investigator per RECIST v1.1 or death from any cause, whichever occurs first. Median DOR was estimated using the Kaplan-Meier method.

    Time frame: From the first objective response to the date of first documentation of disease progression or death, whichever occurs first (up to 2 years and 9 months)

  5. Overall Survival (OS)

    OS was defined as the time from the date of first dose to the date of death due to any cause. Median OS was estimated using the Kaplan-Meier method.

    Time frame: From the first dose of the study treatment to date of death from any cause (up to 2 years and 9 months)

  6. Number of Participants With Treatment Emergent Adverse Events (TEAEs) and Serious TEAEs, Grade 3 or Higher TEAEs, TEAEs Leading to Death, TEAEs Related to Tislelizumab, TEAEs Related to Fruquintinib

    A TEAE was defined as an AE that had an onset date or a worsening in severity from baseline (pre-treatment) on or after the first dose of study drug(s) and up to 30 days following study drug(s) discontinuation or initiation of new anticancer therapy, whichever occurred first determined according to NCI-CTCAE v5.0. Treatment emergent serious Adverse Events (TESAEs): any untoward medical occurrence at any dose: resulted in death; was life threatening; required prolong inpatient hospitalization; resulted in persistent or significant disability/incapacity; resulted in a congenital anomaly/birth defect or was considered a significant medical event by the investigator. AEs were graded for severity using NCI-CTCAE v5.0, where Grade 1: Mild; Grade 2: Moderate; Grade 3: Severe; Grade 4 - Life-threatening consequences; and Grade 5: Death related to AE. The TEAEs leading to death in this data table exclude death due to disease under study.

    Time frame: From the date of the first dose of study drug up to 30 days after the last dose of study drug; up to approximately 2 years and 5 months.

07

Results

Posted Mar 25, 2025

Participant flow

Participant flow — Overall Study
MilestoneGastric Cancer (GC): Tislelizumab and FruquintinibColorectal Cancer (CRC): Tislelizumab and FruquintinibPD-L1 + NSCLC: Tislelizumab and Fruquintinib
Started313122
Completed237
Not completed292815
Withdrew: Death24248
Withdrew: Closed by sponsor445
Withdrew: Lost to follow-up101
Withdrew: Withdrawal by subject001

Outcome measures

PrimaryPart 1: Number of Participants With Dose Limiting Toxicities (DLTs)

A DLT was defined as 1 of the following toxicities (Grade 3 or 4 Hematologic or Nonhematologic toxicities) occurring during the DLT assessment window and considered by the investigator to be related to 1 or more study drugs. All toxicities or adverse events (AEs) were graded according to the National Cancer Institute-Common Terminology Criteria for Adverse Events version 5.0 (NCI-CTCAE v5.0).

Time frame:
Up to 28 Days
Reported as:
Count of participants · Participants
Part 1: Number of Participants With Dose Limiting Toxicities (DLTs)
ParticipantsTislelizumab and Fruquintinib
Part 1: Number of Participants With Dose Limiting Toxicities (DLTs)0
PrimaryPart 1: Recommended Phase 2 Dose (RP2D)

RP2D for Part 2 was determined by evaluating safety and DLTs in Part 1 participants.

Time frame:
Up to 28 Days
Reported as:
Number · milligrams (mg) per day
Part 1: Recommended Phase 2 Dose (RP2D)
milligrams (mg) per dayTislelizumab and Fruquintinib
Part 1: Recommended Phase 2 Dose (RP2D)5.0
PrimaryObjective Response Rate (ORR) as Assessed by the Investigator Based on Response Evaluation Criteria in Solid Tumors (RECIST) Version (v)1.1

ORR was defined as the percentage of participants achieving a best overall response (BOR) of complete response (CR) or partial response (PR). Per RECIST v1.1., CR was defined as disappearance of all target lesions. Any pathological lymph nodes (whether target or non-target) must have reduction in short axis to less than (\<) 10 millimeters (mm). PR was defined as at least a 30 percent (%) decrease in the sum of diameters of target lesions, taking as reference the baseline sum diameters.

Time frame:
From date of randomization until the date of first documented progression or death from any cause, whichever came first (up to 2 years and 9 months)
Reported as:
Number · percentage of participants
Objective Response Rate (ORR) as Assessed by the Investigator Based on Response Evaluation Criteria in Solid Tumors (RECIST) Version (v)1.1
percentage of participantsGastric Cancer (GC): Tislelizumab and FruquintinibColorectal Cancer (CRC): Tislelizumab and FruquintinibPD-L1 + NSCLC: Tislelizumab and Fruquintinib
Objective Response Rate (ORR) as Assessed by the Investigator Based on Response Evaluation Criteria in Solid Tumors (RECIST) Version (v)1.112.9 (3.6 to 29.8)9.7 (2.0 to 25.8)40.9 (20.7 to 63.6)
SecondaryProgression-Free Survival (PFS) as Assessed by Investigator Based on RECIST v1.1

PFS was defined as the time from the date of the first dose of study drug(s) to the date of the confirmed documentation of progressive disease (PD) or death, whichever occurs first. Median PFS was estimated using the Kaplan-Meier method. Per RECIST v1.1, PD was defined as at least a 20% increase in the sum of diameters of target lesions, taking as reference the smallest sum on study.

Time frame:
From date of first dose of study drug until the date of first documented progression or death from any cause, whichever came first (up to 2 years and 9 months)
Reported as:
Median · months
Progression-Free Survival (PFS) as Assessed by Investigator Based on RECIST v1.1
monthsGastric Cancer (GC): Tislelizumab and FruquintinibColorectal Cancer (CRC): Tislelizumab and FruquintinibPD-L1 + NSCLC: Tislelizumab and Fruquintinib
Progression-Free Survival (PFS) as Assessed by Investigator Based on RECIST v1.14.6 (3.4 to 7.4)4.6 (3.6 to 7.2)15.6 (1.8 to NA)
SecondaryDisease Control Rate (DCR) as Assessed by the Investigator Based on RECIST v1.1

DCR was defined as the percentage of participants whose best overall response is CR, PR, or stable disease (SD) as assessed by investigator as per RECIST v1.1. Per RECIST v1.1., CR was defined as disappearance of all target lesions. Any pathological lymph nodes (whether target or non-target) must have reduction in short axis to \< 10 mm. PR was defined as at least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum diameters. SD: Neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD, taking as reference the smallest sum diameters while on study.

Time frame:
From date of randomization until the date of first documented progression or death from any cause, whichever came first (up to 2 years and 9 months)
Reported as:
Number · percentage of participants
Disease Control Rate (DCR) as Assessed by the Investigator Based on RECIST v1.1
percentage of participantsGastric Cancer (GC): Tislelizumab and FruquintinibColorectal Cancer (CRC): Tislelizumab and FruquintinibPD-L1 + NSCLC: Tislelizumab and Fruquintinib
Disease Control Rate (DCR) as Assessed by the Investigator Based on RECIST v1.174.2 (55.4 to 88.1)74.2 (55.4 to 88.1)68.2 (45.1 to 86.1)
SecondaryClinical Benefit Rate (CBR) as Assessed by the Investigator Based on RECIST v1.1

CBR was defined as the percentage of participants whose best overall response is CR, PR, or durable stable disease (SD) as assessed by the investigator per RECIST v1.1. Per RECIST v1.1., CR was defined as disappearance of all target lesions. Any pathological lymph nodes (whether target or non-target) must have reduction in short axis to \< 10 mm. PR was defined as at least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum diameters. SD: Neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD, taking as reference the smallest sum diameters while on study.

Time frame:
From date of randomization until the date of first documented progression or death from any cause, whichever came first (up to 2 years and 9 months)
Reported as:
Number · percentage of participants
Clinical Benefit Rate (CBR) as Assessed by the Investigator Based on RECIST v1.1
percentage of participantsGastric Cancer (GC): Tislelizumab and FruquintinibColorectal Cancer (CRC): Tislelizumab and FruquintinibPD-L1 + NSCLC: Tislelizumab and Fruquintinib
Clinical Benefit Rate (CBR) as Assessed by the Investigator Based on RECIST v1.132.3 (16.7 to 51.4)38.7 (21.8 to 57.8)59.1 (36.4 to 79.3)
SecondaryDuration of Response (DOR) as Assessed by The Investigator Based on RECIST v1.1

DOR was defined as the time from the first occurrence of documented objective response to the time of progression as assessed by investigator per RECIST v1.1 or death from any cause, whichever occurs first. Median DOR was estimated using the Kaplan-Meier method.

Time frame:
From the first objective response to the date of first documentation of disease progression or death, whichever occurs first (up to 2 years and 9 months)
Reported as:
Median · months
Duration of Response (DOR) as Assessed by The Investigator Based on RECIST v1.1
monthsGastric Cancer (GC): Tislelizumab and FruquintinibColorectal Cancer (CRC): Tislelizumab and FruquintinibPD-L1 + NSCLC: Tislelizumab and Fruquintinib
Duration of Response (DOR) as Assessed by The Investigator Based on RECIST v1.1NA (5.6 to NA)11.9 (3.7 to NA)NA (7.7 to NA)
SecondaryOverall Survival (OS)

OS was defined as the time from the date of first dose to the date of death due to any cause. Median OS was estimated using the Kaplan-Meier method.

Time frame:
From the first dose of the study treatment to date of death from any cause (up to 2 years and 9 months)
Reported as:
Median · months
Overall Survival (OS)
monthsGastric Cancer (GC): Tislelizumab and FruquintinibColorectal Cancer (CRC): Tislelizumab and FruquintinibPD-L1 + NSCLC: Tislelizumab and Fruquintinib
Overall Survival (OS)10.5 (5.2 to 14.6)10.0 (4.7 to 15.2)NA (6.0 to NA)
SecondaryNumber of Participants With Treatment Emergent Adverse Events (TEAEs) and Serious TEAEs, Grade 3 or Higher TEAEs, TEAEs Leading to Death, TEAEs Related to Tislelizumab, TEAEs Related to Fruquintinib

A TEAE was defined as an AE that had an onset date or a worsening in severity from baseline (pre-treatment) on or after the first dose of study drug(s) and up to 30 days following study drug(s) discontinuation or initiation of new anticancer therapy, whichever occurred first determined according to NCI-CTCAE v5.0. Treatment emergent serious Adverse Events (TESAEs): any untoward medical occurrence at any dose: resulted in death; was life threatening; required prolong inpatient hospitalization; resulted in persistent or significant disability/incapacity; resulted in a congenital anomaly/birth defect or was considered a significant medical event by the investigator. AEs were graded for severity using NCI-CTCAE v5.0, where Grade 1: Mild; Grade 2: Moderate; Grade 3: Severe; Grade 4 - Life-threatening consequences; and Grade 5: Death related to AE. The TEAEs leading to death in this data table exclude death due to disease under study.

Time frame:
From the date of the first dose of study drug up to 30 days after the last dose of study drug; up to approximately 2 years and 5 months.
Reported as:
Count of participants · Participants
Number of Participants With Treatment Emergent Adverse Events (TEAEs) and Serious TEAEs, Grade 3 or Higher TEAEs, TEAEs Leading to Death, TEAEs Related to Tislelizumab, TEAEs Related to Fruquintinib
ParticipantsGastric Cancer (GC): Tislelizumab and FruquintinibColorectal Cancer (CRC): Tislelizumab and FruquintinibPD-L1 + NSCLC: Tislelizumab and Fruquintinib
TEAEs303122
TESAEs131413
Grade 3 or Higher TEAEs182118
TEAEs Leading to Death301
TEAEs Related to Tislelizumab202216
TEAEs Related to Fruquintinib252619

Adverse events

Collected over All-cause mortality data was collected through the end of study, that is, up to 2 years 9 months. Adverse event data was collected from the date of the first dose of study drug up to 30 days after the last dose of study drug (up to approximately 2 years and 5 months).. Non-serious events are listed at a 3% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Gastric Cancer (GC): Tislelizumab and Fruquintinib24/31 (77.4%)13/31 (41.9%)28/31 (90.3%)
Colorectal Cancer (CRC): Tislelizumab and Fruquintinib24/31 (77.4%)14/31 (45.2%)29/31 (93.5%)
PD-L1 + NSCLC: Tislelizumab and Fruquintinib8/22 (36.4%)13/22 (59.1%)19/22 (86.4%)
Most frequent serious events
Showing 10 of 51
Most frequent serious events
EventGastric Cancer (GC): Tislelizumab and FruquintinibColorectal Cancer (CRC): Tislelizumab and FruquintinibPD-L1 + NSCLC: Tislelizumab and Fruquintinib
DeathGeneral disorders3/310/312/22
General physical health deteriorationGeneral disorders2/313/310/22
HypopituitarismEndocrine disorders0/310/312/22
Hepatic function abnormalHepatobiliary disorders2/310/310/22
COVID-19Infections and infestations0/312/310/22
Cardiac failure acuteCardiac disorders0/310/311/22
Immune-mediated myocarditisCardiac disorders0/310/311/22
Ventricular arrhythmiaCardiac disorders0/310/311/22
Retinal artery occlusionEye disorders0/310/311/22
Intestinal obstructionGastrointestinal disorders0/310/311/22
Most frequent other events
Showing 10 of 186
Most frequent other events
EventGastric Cancer (GC): Tislelizumab and FruquintinibColorectal Cancer (CRC): Tislelizumab and FruquintinibPD-L1 + NSCLC: Tislelizumab and Fruquintinib
ProteinuriaRenal and urinary disorders7/3113/317/22
HypoalbuminaemiaMetabolism and nutrition disorders10/314/319/22
Weight decreasedInvestigations11/313/313/22
AnaemiaBlood and lymphatic system disorders10/316/314/22
HypothyroidismEndocrine disorders7/3110/314/22
DiarrhoeaGastrointestinal disorders2/3110/314/22
CoughRespiratory, thoracic and mediastinal disorders0/310/316/22
HypertensionVascular disorders7/316/315/22
Aspartate aminotransferase increasedInvestigations4/317/313/22
White blood cell count decreasedInvestigations7/311/312/22

Baseline characteristics

Analysis was performed on safety analysis set that included all participants who received at least 1 dose of study drug(s).

Age, Continuous
Age, Continuous(years)Gastric Cancer (GC): Tislelizumab and FruquintinibColorectal Cancer (CRC): Tislelizumab and FruquintinibPD-L1 + NSCLC: Tislelizumab and FruquintinibTotal
Mean59.0 ± 8.7158.8 ± 7.8863.5 ± 11.2860.1 ± 9.29
Sex: Female, Male
Sex: Female, Male(Participants)Gastric Cancer (GC): Tislelizumab and FruquintinibColorectal Cancer (CRC): Tislelizumab and FruquintinibPD-L1 + NSCLC: Tislelizumab and FruquintinibTotal
Female1011526
Male21201758
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Gastric Cancer (GC): Tislelizumab and FruquintinibColorectal Cancer (CRC): Tislelizumab and FruquintinibPD-L1 + NSCLC: Tislelizumab and FruquintinibTotal
American Indian or Alaska Native0000
Asian30312283
Native Hawaiian or Other Pacific Islander0000
Black or African American0000
White0000
More than one race1001
Unknown or Not Reported0000
08

Study locations

13 sites
  • Fujian Cancer Hospital
    Fuzhou, Fujian 350014, China
  • The First Hospital of Lanzhou University
    Lanzhou, Gansu 730000, China
  • Harbin Medical University Cancer Hospital
    Harbin, Heilongjiang 150000, China
  • Henan Cancer Hospital
    Zhengzhou, Henan 450000, China
  • Shandong Cancer Hospital
    Jinan, Shandong 250117, China
  • Liaocheng Peoples Hospital
    Liaocheng, Shandong 252000, China
  • Linyi Cancer Hospital
    Linyi, Shandong 276001, China
  • West China Hospital, Sichuan University
    Chengdu, Sichuan 610041, China
  • Tianjin Medical University Cancer Institute and Hospital
    Tianjin, Tianjin 300060, China
  • Sir Run Run Shaw Hospital, Zhejiang University School of Medicine
    Hangzhou, Zhejiang 310016, China
  • National Cancer Center
    Goyangsi, Gyeonggi-do 10408, Korea, Republic of
  • Seoul National University Bundang Hospital
    Seongnamsi, Gyeonggi-do 13620, Korea, Republic of
  • Asan Medical Center
    Seoul, Seoul Teugbyeolsi 05505, Korea, Republic of
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — BeiGene shares data on completed studies responsibly and provides qualified scientific and medical researchers access to data and supporting documentation for clinical trials in dossiers for medicines and indications after submission and approval in the United States, China, and Europe. Clinical trials supporting subsequent local approvals, new indications, or combination products are eligible for sharing once corresponding regulatory approvals are achieved. BeiGene shares data only when permitted by applicable data privacy and security laws and regulations, when it is feasible to do so without compromising the privacy of study participants, and other considerations. Qualified researchers with appropriate competencies who are engaged in novel scientific research may submit a request for participant-level data with a research proposal for BeiGene review. Research teams must include a biostatistician and sign a Data Sharing Agreement prior to receiving access to clinical trial data.

Supporting information: Study protocol, Statistical analysis plan, Clinical study report

Time frame: See plan description

Access criteria: See plan description

Data sharing details ↗ · beigene.com

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Apr 2021 to primary completion in Feb 2024, 34 months.

Results were first posted in Mar 2025, 1 year 1 month after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 13, 2021
First posted
Jan 20, 2021
StartActual
Apr 19, 2021
Primary completionActual
Feb 22, 2024
CompletionActual
Feb 22, 2024
Results first posted
Mar 25, 2025
Last update
Mar 25, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 25, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT04716634
Lead sponsor
BeiGene
Responsible party
Sponsor
First posted
Jan 20, 2021
Start date
Apr 19, 2021
Primary completion
Feb 22, 2024
Completion
Feb 22, 2024
Results posted
Mar 25, 2025
Last update
Mar 25, 2025

Study contacts

Jian Li
study director · BeiGene

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Mar 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Tislelizumab · HMPL-013

Start the discussion